Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an anti-IGF-1R Antibody for Autoimmune Diseases

06/18/2021 | 09:05am EDT

Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an anti-IGF-1R Antibody for Autoimmune Diseases

  • Lonza will deliver a program tailored to ValenzaBio's needs to enable first-in-human clinical studies
  • Lonza will provide drug substance and drug product manufacturing under accelerated timelines
  • Drug substance manufacturing to be carried out in state-of-the-art cGMP mammalian manufacturing facility in Guangzhou (CN)

Quote from Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza:

'The signing of the manufacturing agreement with ValenzaBio showcases our flexibility in supporting biotech companies of all sizes, and our focused commitment to enabling ValenzaBio to reach the full potential of their innovative therapies on accelerated timelines. We are excited that our new, state-of-the-art Biologics facility in Guangzhou, China will be employed for manufacturing of cGMP drug substance to help bring treatment to patients around the world who suffer from Thyroid Eye Disease (TED).'

Quote from Tatyana Touzova, Chief Operating Officer, ValenzaBio:

'As we prepare to advance VB421 into clinical studies for autoimmune diseases, including Thyroid Eye Disease (TED), in the first half of next year, we are pleased to have Lonza, a global leader in antibody manufacturing, as our trusted partner. Lonza has the knowledge, systems, and production capacity in place to proceed with optimal efficiency during these difficult times for global supply chains. Securing reliable biomanufacturing is a significant challenge for many smaller biopharmaceutical companies. We are grateful to be able to advance the VB421 program immediately in Lonza's new state-of-the-art manufacturing facility.'

Maryland, USA and Basel, Switzerland, 18 June 2021- ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, and Lonza announced today that the companies have a manufacturing agreement in place.

This collaboration is aimed at manufacturing VB421, a potential best-in-class anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody currently under evaluation for the treatment of thyroid eye disease (TED) and other inflammatory disorders. TED is an autoimmune disease causing eye bulging and vision change with a risk of complete vision loss. VB421 is designed to bind IGF-1R, which is believed to play a central role in the pathogenesis of TED. VB421 is currently in an IND-enabling program to support first-in-human studies for the treatment of TED and other autoimmune and fibrotic diseases.

Under the terms of the agreement, Lonza will leverage its global network and local operation capabilities to provide ValenzaBio with clinical materials' supply. The scope will include drug substance (DS) manufacturing at Lonza's new state-of-the-art cGMP mammalian facility in Guangzhou (CN) as well as management of drug product manufacturing.

The main production platform will utilize Lonza's GS Xceed® Expression System, which is highly recognized in the industry and covers various techniques and commercialized processes such as host cells, expression vectors and optimized culture media.


Lonza Group Ltd. published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2021 13:04:06 UTC.

ę Publicnow 2021
All news about LONZA GROUP AG
02:08aLONZA : Committee Member Offloads Shares for $1 Million
07/28LONZA : Credit Suisse Lifts Price Target on Lonza Group, Maintains Outperform Re..
07/28MODERNA : Expects COVID-19 Vaccine Supply Issues To Persist Outside US
07/27Moderna says COVID-19 vaccine supply outside United States to slow down
07/27Manufacturing Woes Plague Shipment of Moderna COVID-19 Jab to South Korea
07/27Moderna says COVID-19 vaccine supply outside United States to slow down
07/26LONZA : Equita SIM SpA Lifts Price Target on Lonza Group, Maintains Buy Recommen..
07/26ANALYST RECOMMENDATIONS : Casey's, D.R. Horton, Microsoft, Unilever, Veoneer...
07/23European Stocks Rally After Dovish ECB Comments, Surge in PMI Services and Ou..
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
More news
Sales 2021 5 090 M 5 599 M 5 599 M
Net income 2021 792 M 871 M 871 M
Net Debt 2021 86,4 M 95,1 M 95,1 M
P/E ratio 2021 64,9x
Yield 2021 0,46%
Capitalization 50 928 M 55 738 M 56 021 M
EV / Sales 2021 10,0x
EV / Sales 2022 9,01x
Nbr of Employees 14 405
Free-Float 99,6%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 685,60 CHF
Average target price 725,33 CHF
Spread / Average Target 5,79%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG20.53%55 738
MODERNA, INC.234.37%140 262
CELLTRION, INC.-27.16%30 887
SEAGEN INC.-16.58%26 514